NEW YORK (GenomeWeb News) – The University of Geneva, Geneva University Hospitals, and the SIB Swiss Institute of Bioinformatics today announced a strategic collaboration with Roche in translational medical research.
The deal will initially be directed at basic research, bioinformatics, and biomarker development in cardiology, hematology, pathology, and applied human toxicology, SIB said. It added that the partnership will leverage "the scientific excellence in Geneva" and Roche's internal research to develop better medical diagnostics and treatments tailored to patients.
In a statement, Jacky Vonderscher, global head of Translational Research Sciences at Roche, said that Geneva is a hub of specialists in proteomics and bioinformatics "with a strong translational set-up between labs and the clinic. This close link between diverse disciplines is absolutely key to better understand the diseases at the molecular level and ultimately to discover new diagnostic and therapeutic interventions."
Projects will be chosen based on mutual interests of the partners. Financial and other terms of the deal were not disclosed.
"The collaboration with Geneva is really important to us as it will focus on the predictability of safety assessment," Thomas Singer, global head of Non Clinical Safety at Roche, said. "The ability to forecast the side effects of medicine greatly grows with the use of human cells revealing the pharmacological and toxicological pathways."